Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma

Frontiers in Immunology

Cui Chen²  Hang Yang³  Man Nie³  Kang-Ming Huang³  Xiao-Qing Sun³  Xiao-Hua He³  Jia-Jia Huang³  Zhi-Ming Li³  Peng Sun³  Yu Wang³ 

[1] Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China;State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China;

关键词: natural killer/T cell lymphoma;    anlotinib;    anti-PD-1 antibody;    pegaspargase;    radiotherapy;   

DOI  :  10.3389/fimmu.2022.766200

来源: DOAJ

【 摘 要 】

Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m2 were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn’t report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance.

【 授权许可】

Unknown